Viva Biotech Holdings provided consolidated earnings guidance for the six months ended June 30, 2021. The board of directors of the Company informed the shareholders of the Company ("Shareholders") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2021 (the "Period") and information currently available, the Group expects that the revenue for the Period will increase by no less than RMB 800 million or over 400% to approximately RMB 1,000 million as compared to that of the six months ended June 30, 2020 (the "Corresponding Period Last Year"). The Group expects to record a net profit of no less than RMB 85 million for the Period as compared with a net loss of RMB 530.3 million for the Corresponding Period Last Year. The Group expects to record a net profit attributable to the equity shareholders of the Company of no less than RMB 75 million for the Period as compared with a net loss attributable to the equity shareholders of the Company of RMB 530.3 million for the Corresponding Period Last Year.